Cadila Healthcare recently announced the success of their ZyCOV-D (zydus cadila) vaccine in its first round of plasmid DNA vaccine. The results proved that the vaccine is “safe” and “well tolerated” in the first phase of the clinical trials. Pankaj R Patel, Chairman, Zydus Cadila said, “The Phase I dosing to establish the safety of ZyCoV-D is an important milestone,”
The trail was endorsed by the independent Data Safety Monitoring Board (DSMB) wherein, all the subjects were closely monitored.
The phase 2 of the vaccine is set to from August 6. This will include about 1,000 healthy adult volunteers as part of the Adaptive Phase I/II dose escalation, multicentric, randomised, double-blind placebo controlled study.
Since the announcement of the results the shares of the company have rocketed to nearly 2 per cent in early trades on BSE at ₹409.60.
Additionally, Zydus is supported by National Biopharma Mission, BIRAC, Department of Biotechnology, Government of India in the development of ZyCoV-D.